Nicotine therapeutic benefits: Difference between revisions

added to suggested studies
(added to suggested studies)
Line 647: Line 647:
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson's disease]===
===2017 [https://www.ncbi.nlm.nih.gov/pubmed/27940486 Moist smokeless tobacco (Snus) use and risk of Parkinson's disease]===
*Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%.
*Smoke-free nicotine appears to reduce the risk of Parkinson’s disease by 60%.
* different website same study? [[Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease|https://academic.oup.com/ije/article/46/3/872/2656164]]
*different website same study? [Moist smokeless tobacco (Snus) use and risk of Parkinson’s disease|https://academic.oup.com/ije/article/46/3/872/2656164]
 
===2020 [https://n.neurology.org/content/neurology/94/20/e2132.full.pdf Tobacco smoking and the risk of Parkinson disease A 65-year follow-up of 30,000 male British doctors]


===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===
===[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC526783/ Nicotine as Therapy]===